SARS-CoV-2 spike glycoprotein conserved epitope (SARS-CoV-2 S conserved epitope)

The SARS-CoV-2 spike (S) glycoprotein conserved epitope refers to specific, highly stable regions of the viral spike protein that remain relatively unchanged across different variants of concern and related sarbecoviruses (UniProt P0DTC2). These epitopes are primarily located within the receptor-binding domain (RBD) or the S2 subunit, which is responsible for membrane fusion (Pinto et al., Nature 2020). Because these regions are critical for the virus's structural integrity or functional entry into host cells, they are less prone to mutations that would compromise viral fitness (Veesler et al., Science 2020). Targeting these conserved sites is a key strategy in developing variant-proof monoclonal antibodies and universal vaccines (Zhou et al., Nature Communications 2022). Drugs like Sotrovimab interact with these epitopes to neutralize the virus by either sterically hindering the interaction with the human ACE2 receptor or by preventing the S2 subunit from undergoing the necessary structural transitions for fusion (NIH, COVID-19 Treatment Guidelines). Consequently, these epitopes are vital for maintaining therapeutic efficacy as the virus continues to evolve.

Other names

Pan-sarbecovirus epitopeConserved RBD epitopeS2 subunit conserved epitopeStem helix epitopeS309-binding siteClass 4 RBD epitope

Neutralization of viral infection by sterically blocking the interaction between the viral receptor-binding domain and the host ACE2 receptor, or by inhibiting the conformational changes in the S2 subunit required for membrane fusion.